Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post.

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

The Vanderbilt Dayani Center for Health and Wellness is now offering exercise planning consultations for people with cancer diagnoses.

David Cortez, PhD, has been named associate director for Basic Science Research at Vanderbilt-Ingram Cancer Center (VICC).

New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.